"Profit Warning" CF PHARMTECH forecasts last year's profit to decrease to a maximum of 3 million RMB

CF PHARMTECH (02652.HK) issued a profit warning, expecting a profit of between RMB 2 million and RMB 3 million for the fiscal year 2025, compared to RMB 21.09 million recorded in the previous year; adjusted net profit is expected to be between RMB 30 million and RMB 35 million, down from RMB 51.87 million last year. Revenue is expected to be between RMB 410 million and RMB 450 million, compared to RMB 608 million recorded last year. The reasons include a decrease in average selling prices after the completion of updates to the group's main product arrangements; a decline in the overall incidence of respiratory infections in 2025, which reduced market demand for the group's inhalation formulation products; increased R&D expenses; and the recognition of one-time expenses related to the listing